AR105728A1 - Lisobactina para su uso en el tratamiento de la mastitis bovina - Google Patents

Lisobactina para su uso en el tratamiento de la mastitis bovina

Info

Publication number
AR105728A1
AR105728A1 ARP160102525A ARP160102525A AR105728A1 AR 105728 A1 AR105728 A1 AR 105728A1 AR P160102525 A ARP160102525 A AR P160102525A AR P160102525 A ARP160102525 A AR P160102525A AR 105728 A1 AR105728 A1 AR 105728A1
Authority
AR
Argentina
Prior art keywords
lisobactin
treatment
bovine mastitis
bovine
mastitis
Prior art date
Application number
ARP160102525A
Other languages
English (en)
Inventor
Kbberling Johannes
Wiehl Wolfgang
Fraatz Kristine
Daube Gert
Flker Stefan
Schiffer Guido
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of AR105728A1 publication Critical patent/AR105728A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Lisobactina para su uso en el tratamiento de la mastitis bovina. Reivindicación 10: Composición farmacéutica formulada para la administración intramamaria en mamas bovinas, caracterizada por que la composición comprende lisobactina.
ARP160102525A 2015-08-17 2016-08-17 Lisobactina para su uso en el tratamiento de la mastitis bovina AR105728A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15181209 2015-08-17

Publications (1)

Publication Number Publication Date
AR105728A1 true AR105728A1 (es) 2017-11-01

Family

ID=53871958

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160102525A AR105728A1 (es) 2015-08-17 2016-08-17 Lisobactina para su uso en el tratamiento de la mastitis bovina

Country Status (27)

Country Link
US (2) US20180346518A1 (es)
EP (1) EP3337494B1 (es)
JP (1) JP6921805B2 (es)
KR (1) KR20180040674A (es)
CN (1) CN107921088B (es)
AR (1) AR105728A1 (es)
AU (1) AU2016310221B2 (es)
BR (1) BR112018003150A2 (es)
CA (1) CA2995648C (es)
CO (1) CO2018001531A2 (es)
CR (1) CR20180110A (es)
DK (1) DK3337494T3 (es)
ES (1) ES2788734T3 (es)
HR (1) HRP20200427T1 (es)
HU (1) HUE048864T2 (es)
IL (1) IL257342A (es)
LT (1) LT3337494T (es)
MX (1) MX2018002020A (es)
PE (1) PE20180574A1 (es)
PH (1) PH12018500339A1 (es)
PL (1) PL3337494T3 (es)
PT (1) PT3337494T (es)
RU (1) RU2741764C2 (es)
SI (1) SI3337494T1 (es)
TW (1) TW201717991A (es)
WO (1) WO2017029271A1 (es)
ZA (1) ZA201801788B (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1266247A (en) 1985-03-25 1990-02-27 Adrienne A. Tymiak Antibiotic prepared from lysobacter sp. sc 14,067
JPH01132600A (ja) 1987-11-17 1989-05-25 Shionogi & Co Ltd カタノシンａおよびｂならびにその製造法
DE10320781A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag Acylierte Nonadepsipeptide
DE102004051025A1 (de) 2004-10-20 2006-04-27 Bayer Healthcare Ag Substituierte Nonadepsipeptide
DE102004051024A1 (de) 2004-10-20 2006-04-27 Bayer Healthcare Ag Heterocyclyl-substituierte Nonadepsipeptide
DE102004051023A1 (de) 2004-10-20 2006-05-04 Bayer Healthcare Ag Desoxo-Nonadepsipeptide
DE102004053407A1 (de) * 2004-11-05 2006-05-11 Bayer Healthcare Ag Acylierte Nonadepsipeptide II
DE102004053410A1 (de) 2004-11-05 2006-05-11 Bayer Healthcare Ag Cyclische Nonadepsipeptidamide
DE102004053409A1 (de) 2004-11-05 2006-05-11 Bayer Healthcare Ag Verfahren zur gezielten Herstellung von Lysobactinfragmenten
DE102006003443A1 (de) 2006-01-25 2007-07-26 Aicuris Gmbh & Co. Kg Asparagin-10-substituierte Nonadepsipeptide
DE102006018250A1 (de) 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Verfahren zum Herstellen von cyclischen Depsipeptiden
DE102006018080A1 (de) 2006-04-13 2007-10-18 Aicuris Gmbh & Co. Kg Lysobactinamide

Also Published As

Publication number Publication date
CR20180110A (es) 2018-04-27
CA2995648A1 (en) 2017-02-23
AU2016310221B2 (en) 2021-08-05
WO2017029271A1 (en) 2017-02-23
PE20180574A1 (es) 2018-04-04
HUE048864T2 (hu) 2020-08-28
EP3337494A1 (en) 2018-06-27
ZA201801788B (en) 2019-10-30
PT3337494T (pt) 2020-05-11
CN107921088A (zh) 2018-04-17
RU2741764C2 (ru) 2021-01-28
US20180346518A1 (en) 2018-12-06
CA2995648C (en) 2024-02-20
TW201717991A (zh) 2017-06-01
PH12018500339A1 (en) 2018-08-20
ES2788734T3 (es) 2020-10-22
LT3337494T (lt) 2020-04-10
PL3337494T3 (pl) 2020-09-07
EP3337494B1 (en) 2020-03-11
US20230125394A1 (en) 2023-04-27
AU2016310221A1 (en) 2018-03-01
KR20180040674A (ko) 2018-04-20
DK3337494T3 (da) 2020-05-25
RU2018109421A3 (es) 2019-11-13
JP2018523677A (ja) 2018-08-23
SI3337494T1 (sl) 2020-06-30
CN107921088B (zh) 2022-05-27
BR112018003150A2 (pt) 2018-09-25
HRP20200427T1 (hr) 2020-06-12
IL257342A (en) 2018-03-29
MX2018002020A (es) 2018-06-15
JP6921805B2 (ja) 2021-08-18
CO2018001531A2 (es) 2018-07-10
RU2018109421A (ru) 2019-09-19

Similar Documents

Publication Publication Date Title
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
SV2018005610A (es) Derivados de oxopiridina sustituidos
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CL2018001171A1 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
AR100215A1 (es) Conjugados de anticuerpo-fármaco anti-ptk7
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
BR112015015891A8 (pt) Composição farmacêutica de solução sólida, e, uso de uma composição farmacêutica
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
CO2019008103A2 (es) Composiciones farmacéuticas para terapia de combinación
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
CO2017002506A2 (es) Nuevos activadores de la guanilato ciclasa soluble y su uso
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CO2017010621A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
EA201791716A1 (ru) Фармацевтический состав
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
CO2018011420A2 (es) Formulaciones líquidas de fosfaplatino

Legal Events

Date Code Title Description
FB Suspension of granting procedure